| __timestamp | Apellis Pharmaceuticals, Inc. | Galapagos NV |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 111110000 |
| Thursday, January 1, 2015 | 13730311 | 129714000 |
| Friday, January 1, 2016 | 22978599 | 139574000 |
| Sunday, January 1, 2017 | 40303878 | 218502000 |
| Monday, January 1, 2018 | 105285576 | 322876000 |
| Tuesday, January 1, 2019 | 220968770 | 427320000 |
| Wednesday, January 1, 2020 | 299921000 | 523667000 |
| Friday, January 1, 2021 | 420869000 | 491707000 |
| Saturday, January 1, 2022 | 387236000 | 515083000 |
| Sunday, January 1, 2023 | 354387000 | 241294000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Apellis Pharmaceuticals and Galapagos NV have demonstrated contrasting trajectories in their R&D investments. From 2014 to 2023, Galapagos NV consistently outpaced Apellis, peaking in 2020 with a 370% increase from its 2014 spending. Meanwhile, Apellis showed a remarkable growth, with its R&D expenses surging by over 4,000% during the same period, reaching a high in 2021. However, 2023 marked a shift, with Galapagos reducing its R&D budget by 54% from its 2020 peak, while Apellis maintained a robust investment, albeit slightly lower than its 2021 zenith. This dynamic reflects the strategic priorities and market conditions influencing these biotech giants, offering a glimpse into their future potential.
Analyzing R&D Budgets: Merck & Co., Inc. vs Apellis Pharmaceuticals, Inc.
Comparing Innovation Spending: Gilead Sciences, Inc. and Galapagos NV
Research and Development Investment: Teva Pharmaceutical Industries Limited vs Galapagos NV
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Apellis Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Madrigal Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc.
R&D Spending Showdown: Madrigal Pharmaceuticals, Inc. vs Galapagos NV
R&D Spending Showdown: Apellis Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Xencor, Inc.
ACADIA Pharmaceuticals Inc. vs Galapagos NV: Strategic Focus on R&D Spending
R&D Spending Showdown: Mesoblast Limited vs Galapagos NV